Moleculin Biotech is trading 6.00% up in pre-market at $8.97 on November 5, after interim results from its pivotal Phase 2/3 Annamycin trial showed complete remission rates of 43% and 36% in the treatment arms, versus 12% for placebo.
- November 4 close: $8.46; the independent monitoring committee recommended continuing the study without amendment.
- Results are slated for presentation at the December 2026 ASH meeting; the next interim analysis is expected in early 2027.
- The broader biotech sector is also higher pre-market.